United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2014_register
executive
2014-10-07
article
Draft Guidance for Industry on Best Practices in Developing Proprietary Names for Drugs; Reopening of the Comment Period
Notices
D09002ee1bdc3da58
D09002ee1bdc3dacd
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
Food and Drug Administration
originator
org
United States Government Agency or Subagency
The Food and Drug Administration (FDA) is reopening the comment period for the draft guidance entitled ``Best Practices in Developing Proprietary Names for Drugs,'' which published in the Federal Register of May 29, 2014 (79 FR 30852). FDA is reopening the comment period in response to several requests for additional time and to allow interested persons more time to submit comments.
79 FR 47654
https://www.govinfo.gov/app/details/FR-2014-08-14/2014-19261
2014-19261
fr14au14-66
4164-01-P
Docket No. FDA-2014-D-0622
https://www.govinfo.gov/app/details/FR-2014-08-14/2014-19261
https://www.govinfo.gov/content/pkg/FR-2014-08-14/html/2014-19261.htm
https://www.govinfo.gov/content/pkg/FR-2014-08-14/pdf/2014-19261.pdf
1 p.
47654
47654
79 FR 47654
Draft Guidance for Industry on Best Practices in Developing Proprietary Names for Drugs; Reopening of the Comment Period; Federal Register Vol. 79, Issue
NOTICE
2014-19261
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. FDA-2014-D-0622
4164-01-P
2014-19261
Notice; reopening of the comment period.
The Food and Drug Administration (FDA) is reopening the comment period for the draft guidance entitled ``Best Practices in Developing Proprietary Names for Drugs,'' which published in the Federal Register of May 29, 2014 (79 FR 30852). FDA is reopening the comment period in response to several requests for additional time and to allow interested persons more time to submit comments.
Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comments on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by September 15, 2014.
Kellie Taylor, Center for Drug Evaluation and Research, Food and Drug Administration, Office of Surveillance and Epidemiology, 10903 New Hampshire Ave., Bldg. 22, Rm. 4418, Silver Spring, MD 20993-0002, 301-796-0157.
Guidance for Industry and Staff:
Best Practices in Developing Proprietary Names for Drugs
,
http://www.regulations.gov
Federal Register
Vol. 79, no. 157
Office of the Federal Register, National Archives and Records Administration
2014-08-14
continuing
daily
deposited
born digital
472 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2014-08-14
P0b002ee189da2e4f
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr14au14
https://www.govinfo.gov/app/details/FR-2014-08-14
https://www.govinfo.gov/content/pkg/FR-2014-08-14/pdf/FR-2014-08-14.pdf
https://www.govinfo.gov/content/pkg/FR-2014-08-14/xml/FR-2014-08-14.xml
fdlp
47551
48014
DGPO
2014-10-07
2023-04-29
FR-2014-08-14
machine generated
eng
FR
FR-2014-08-14
79
157